𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma : A Phase II study

✍ Scribed by Michael Weller; Johannes Streffer; Wolfgang Wick; Rolf D. Kortmann; Eckart Heiss; Wilhelm Küker; Richard Meyermann; Johannes Dichgans; Michael Bamberg

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
66 KB
Volume
91
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of temozolomide without r
Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations
✍ Olivier-L. Chinot; Maryline Barrie; Elisabeth Frauger; Henry Dufour; Dominique F 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 1 views

## Abstract ## BACKGROUND Currently, the survival of patients age > 70 years with glioblastoma multiforme (GBM) ranges from 4 months to 6 months, although radiotherapy and/or chemotherapy may prolong survival in certain subgroups. Temozolomide is an oral chemotherapeutic agent with efficacy agains

A multicentre phase II trial of gemcitab
A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03
✍ F. Hitz; G. Martinelli; E. Zucca; R. von Moos; W. Mingrone; M. Simcock; J. Peter 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

## Abstract Mantle cell lymphoma (MCL) has a poor prognosis with often short and incomplete remissions. We aimed to test the efficacy and tolerability of gemcitabine in treating MCL. Gemcitabine was given in doses of 1000 mg/m^2^ as a 30 min infusion on days 1 and 8 of each 3 week cycle for a maxim

Phase I/II study of a combined gemcitabi
Phase I/II study of a combined gemcitabine, etoposide, and cisplatin chemotherapy regimen for metastatic urothelial carcinoma
✍ Tetsuro Tsukamoto; Junji Yonese; Yuhei Ohkubo; Iwao Fukui 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB

## Abstract ## BACKGROUND The authors attempted to determine the maximum tolerated dose (MTD) of gemcitabine in combination with etoposide and cisplatin as a chemotherapy regimen and investigated the safety and antitumor activity with the recommended doses of gemcitabine with etoposide and cisplat

Benefits of interferon-β and temozolomid
Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter : A multicenter study
✍ Kazuya Motomura; Atsushi Natsume; Yugo Kishida; Hiroyuki Higashi; Yutaka Kondo; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 409 KB

## Abstract ## BACKGROUND: The aim of the current study was to catalog genomic and epigenomic abnormalities in newly diagnosed glioblastoma patients and determine the correlation among clinical, genetic, and epigenetic profiles and clinical outcome. ## METHODS: This study retrospectively include